Actuate Therapeutics Inc (ACTU) Stock Score, Valuation & Financial Research

Actuate Therapeutics Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ACTU

Actuate Therapeutics Inc does not currently have a complete Wall Street Score. The stored market price is USD 0.78. These figures are a research snapshot, not a buy or sell recommendation.

What Actuate Therapeutics Inc does

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Actuate Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital to fund the research and development of its lead drug candidate, elraglusib, with the long-term goal of obtaining regulatory approval and commercializing its therapeutic pipeline.

Products and services

  • The company's primary product candidate is elraglusib, a small molecule GSK-3 inhibitor designed to reduce inflammation, chemoresistance, and tumor progression in patients with cancer.

Brands and product families

  • elraglusib — Lead small molecule GSK-3 inhibitor drug candidate. Source

Customer types

Patients with pancreatic cancer; Patients with Ewing sarcoma; Patients with solid cancers.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party organizations for clinical trial management, drug manufacturing, and other development services; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Lantern Pharma Inc. — A research and development collaboration to leverage Lantern Pharma's artificial intelligence platform to understand the effects of elraglusib and identify susceptible patient subtypes. Source

Business strengths to evaluate

  • Orphan Drug and Fast Track designations for elraglusib in pancreatic cancer Source

Business risks and research considerations

  • Lack of product revenue and history of operating losses Source
  • Need for substantial additional capital to fund clinical development Source
  • Inherent risks and uncertainties in clinical trials and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ACTU financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.78
Market capitalization:
18.65M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -20.45M
Free cash flow:
USD -19.21M
Cash:
USD 4.43M
Total debt:
USD 404.99K
EPS:
USD -0.89

What stands out

  • Free cash flow is USD -19.21M, negative for the stored period.
  • The balance sheet shows USD 4.43M of cash versus USD 404.99K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.02M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ACTU

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ACTU fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ACTU likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ACTU to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ACTU's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ACTU

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.